As a consequence of the BRAF inhibitor treatment, activating ligands MICA, ULBP3 and PVR are decreased on melanoma cells, thus contributing to diminished NK cell activation and further support of immune escape [98]. The gene discussed is BRAF; the disease is melanoma.